Supplemental material
Journal of Medical Economics
Volume 25, 2022 - Issue 1
Oncology
Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US
Olalekan O. Oluwolea Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
https://orcid.org/0000-0001-8525-9641
https://orcid.org/0000-0001-8525-9641, Rongzhe Liub OPEN Health Company, Bethesda, MD, USACorrespondence[email protected]
https://orcid.org/0000-0001-8316-6089
https://orcid.org/0000-0001-8316-6089, Ibrahim Diakiteb OPEN Health Company, Bethesda, MD, USAhttps://orcid.org/0000-0001-7151-4330
https://orcid.org/0000-0001-7151-4330, Chaoling Fengc Kite, A Gilead Company, Santa Monica, CA, USAhttps://orcid.org/0000-0003-4654-4305
https://orcid.org/0000-0003-4654-4305, , Iman Nourhusseinb OPEN Health Company, Bethesda, MD, USAhttps://orcid.org/0000-0003-3271-7439
https://orcid.org/0000-0003-3271-7439, Julia Thornton Sniderc Kite, A Gilead Company, Santa Monica, CA, USAhttps://orcid.org/0000-0003-0017-4863
https://orcid.org/0000-0003-0017-4863 & Frederick L. Locked Moffitt Cancer Center, Tampa, FL, USAhttps://orcid.org/0000-0001-9063-6691
https://orcid.org/0000-0001-9063-6691 show allRelated Research Data
Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy in the US
Source:
Taylor & Francis
Linking provided by
